Understand · Treat · Recover

Acute Lymphoblastic Leukemia (ALL)

ALL affects immature lymphoid cells. Treatment often has several phases, even when the first marrow response is excellent.

For patients and families. This education does not replace an individual treatment plan. Do not start, stop or change medicines without the treating team.

Chapter 5 of 20 · B · Leukemia

B-ALL, T-ALL and age

Flow cytometry distinguishes B-cell and T-cell ALL and helps separate them from other acute leukemias. B-ALL is more common; T-ALL may involve a chest mass. Childhood ALL differs from adult ALL in biology, drug tolerance and outcomes. Many children can be cured, but each child needs risk-adapted specialist treatment. Adolescents and suitable young adults may receive pediatric-inspired regimens; older adults often need adapted approaches.

Philadelphia chromosome and other tests

The Philadelphia chromosome creates the BCR::ABL1 fusion. In ALL, this finding directs the use of a tyrosine kinase inhibitor (TKI), alongside other treatment. It does not mean the patient simply has chronic-phase CML. Other genetic findings and the early treatment response also matter. Cytogenetic and molecular results complement, rather than replace, flow cytometry and marrow assessment.

Why treatment has phases

PhasePurpose
InductionBring the leukemia into remission
Consolidation / intensificationTreat remaining cells and reduce recurrence
MaintenanceUse longer-term treatment in many protocols to help maintain remission
CNS-directed treatmentProtect or treat the brain and spinal-fluid compartment throughout relevant phases

The sequence and duration vary by age, subtype, protocol and whether immunotherapy or transplantation is used. Feeling well or having normal counts is not a reason to stop scheduled treatment. Supportive medicines and regular tests are part of the programme.

Brain and spinal-fluid protection

The central nervous system (CNS) can act as a sanctuary site. Treatment may include intrathecal medicine delivered into cerebrospinal fluid through a lumbar puncture and systemic drugs that reach this compartment. A negative initial CSF test does not remove the need for preventive CNS-directed therapy. Cranial radiation is reserved for selected situations rather than given routinely to every patient.

MRD and modern immunotherapy

MRD testing detects small amounts of leukemia using sensitive flow or molecular methods. Timing, sample quality and the test’s sensitivity affect interpretation. Blinatumomab, a bispecific antibody, and inotuzumab ozogamicin, an antibody-drug conjugate, are options in selected B-ALL settings. Blinatumomab also has an established role within some earlier treatment programmes, not only after relapse. CAR-T therapy can be an option for eligible B-ALL patients. These B-cell treatments must not be assumed to work for T-ALL; many cellular approaches for T-ALL remain investigational.

Transplant, practical risks and outlook

Allogeneic transplantation is considered for selected high-risk disease, persistent MRD or relapse, rather than automatically for everyone. Treatment can cause infections, low counts and organ toxicities. Steroids and asparaginase-containing regimens also need monitoring for metabolic, clotting, pancreatic and liver complications. Families should have a written emergency plan and an uninterrupted medicine supply. Cure prospects depend on age, biology, response and care delivery; MRD-negative remission is encouraging but not a guarantee.

Take-home message

The full treatment programme and MRD response matter, not only the first normal marrow.

Common questions

Can treatment stop when the marrow looks normal?

No. The later phases are designed to treat cells that routine microscopy cannot see. Changes must follow the treating protocol.

Does everyone with ALL need CAR-T?

No. Many patients are treated successfully without it. Eligibility depends on disease type, prior therapy, health and access.

Understanding chemotherapy

Read the complete Chemotherapy Guide

Sources and further reading

Cancer Aware supports patients and families worldwide. Treatment availability, approvals and care pathways vary by country; discuss local options with your healthcare team.